 phase II trial intraperiton cisplatin etoposid salvag treatment minim residu ovarian carcinoma phase II studi intraperiton IP cisplatin cddp etoposid salvag therapi patient ovarian cancer persist diseas primari system chemotherapi residu diseas cm eleven cours IP chemotherapi cddp patient intraven IV thiosulf protect treatment week median cycl assess patient free diseas end treatment normal physic exam tomograph CT scan periton cytolog patient partial respons patient reexplor end treatment patholog complet remiss patient posit periton wash evid persist diseas median surviv patient month first day IP treatment month diagnosi major toxic myelosuppress median nadir wbc granulocyt platelet count cumul renal damag hypomagnesemia chemic periton IP cddp patholog complet remiss second-lin regimen patient ovarian cancer system cisplatin-bas therapi cm diseas